Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while ...

In this video, Shyam Natarajan, PhD, discusses future research involving Unfold AI. He is an author of the recent BJUI Compass study, “Extracapsular extension risk assessment using an artificial ...

“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," ...

No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort. Transperineal biopsy yielded a lower risk of infectious complications while ...

“Thriving in Urology” is a new video series hosted by urologist Amy M. Pearlman, MD, of the Prime Institute in Coral Gables, Florida.Each video will contain conversations on combating burnout by ...

“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," ...

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01). Serum glycoproteins involved in complement cascade and lipid metabolism ...

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD. Treatment of locally advanced or metastatic urothelial carcinoma with ...

The term interstitial cystitis/bladder pain syndrome (IC/BPS) describes a heterogeneous lower urinary tract disorder that is challenging to diagnose and notoriously difficult to manage effectively.

Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.

"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP. In this ...